Published in Proc Natl Acad Sci U S A on October 15, 1996
An HSV vector system for selection of ligand-gated ion channel modulators. Nat Methods (2007) 1.57
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur J Neurosci (2008) 1.12
Nucleolin is required for an efficient herpes simplex virus type 1 infection. J Virol (2008) 1.07
Soluble V domain of Nectin-1/HveC enables entry of herpes simplex virus type 1 (HSV-1) into HSV-resistant cells by binding to viral glycoprotein D. J Virol (2006) 1.07
Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol (2000) 0.98
Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol (1998) 0.97
Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol (1999) 0.95
Herpes simplex virus type 1 ICP0 protein mediates activation of adeno-associated virus type 2 rep gene expression from a latent integrated form. J Virol (2004) 0.92
Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci U S A (1999) 0.92
Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther (2009) 0.91
The role of delta opioid receptors in the anxiolytic actions of benzodiazepines. Pharmacol Biochem Behav (2006) 0.90
Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther (2008) 0.89
HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (1999) 0.88
High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J Invest Dermatol (2008) 0.85
The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol (2004) 0.84
Relief of pain induced by varicella-zoster virus in a rat model of post-herpetic neuralgia using a herpes simplex virus vector expressing enkephalin. Gene Ther (2014) 0.83
Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol (2004) 0.83
Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception. Hum Gene Ther (2013) 0.81
Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther (2010) 0.81
Herpes simplex viral vectors: late bloomers with big potential. Hum Gene Ther (2014) 0.81
Chapter seven--Cancer treatment with gene therapy and radiation therapy. Adv Cancer Res (2012) 0.80
A herpes simplex virus vector system for expression of complex cellular cDNA libraries. J Virol (2010) 0.79
Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. J Gen Virol (2015) 0.78
Intramuscular electroporation with the pro-opiomelanocortin gene in rat adjuvant arthritis. Arthritis Res Ther (2003) 0.77
Immune responses to herpesviral vectors. Hum Gene Ther (2009) 0.76
Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol (1985) 8.12
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell (1994) 4.70
Collaborative complementation study of temperature-sensitive mutants of herpes simplex virus types 1 and 2. J Virol (1978) 4.31
Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J Virol (1989) 4.18
Control of mRNA stability by the virion host shutoff function of herpes simplex virus. J Virol (1989) 2.65
Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol (1992) 1.79
Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J Virol (1994) 1.51
Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci (1996) 1.35
Long-term promoter activity during herpes simplex virus latency. J Virol (1994) 1.27
In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther (1992) 1.11
Antiviral activity of herpes simplex virus vectors expressing murine alpha 1-interferon. Gene Ther (1995) 1.03
Cloning of herpes simplex virus type 1 sequences representing the whole genome. J Virol (1981) 5.66
Promoter-regulatory region of the major immediate early gene of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 5.04
Transcriptional and genetic analyses of the herpes simplex virus type 1 genome: coordinates 0.29 to 0.45. J Virol (1984) 4.09
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J Virol (1987) 3.74
CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med (2000) 3.62
Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem (1994) 3.14
High-frequency transfer of cloned herpes simplex virus type 1 sequences to mammalian cells by protoplast fusion. Mol Cell Biol (1981) 2.97
Physical mapping of the mutation in an antigenic variant of herpes simplex virus type 1 by use of an immunoreactive plaque assay. J Virol (1983) 2.96
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest (1992) 2.80
Mutations in herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA. J Virol (1993) 2.79
Transcriptional control signals of a herpes simplex virus type 1 late (gamma 2) gene lie within bases -34 to +124 relative to the 5' terminus of the mRNA. Mol Cell Biol (1986) 2.65
Blindness and vision impairment in a rural south Indian population: the Aravind Comprehensive Eye Survey. Ophthalmology (2003) 2.64
A population based eye survey of older adults in Tirunelveli district of south India: blindness, cataract surgery, and visual outcomes. Br J Ophthalmol (2002) 2.60
The pseudorabies virus gII gene is closely related to the gB glycoprotein gene of herpes simplex virus. J Virol (1987) 2.58
Rapid identification of nonessential genes of herpes simplex virus type 1 by Tn5 mutagenesis. Science (1987) 2.57
Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest (1995) 2.48
Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res (1998) 2.35
Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science (1979) 2.22
Microbial keratitis in South India: influence of risk factors, climate, and geographical variation. Ophthalmic Epidemiol (2007) 2.19
Expression of herpes simplex virus beta and gamma genes integrated in mammalian cells and their induction by an alpha gene product. Mol Cell Biol (1983) 2.15
A specific 15-bp TATA box promoter element is required for expression of a herpes simplex virus type 1 late gene. Genes Dev (1988) 2.11
Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration. J Virol (1988) 1.94
Immune interactions with cells infected with herpes simplex virus: antibodies to radioiodinated surface antigens. J Immunol (1977) 1.94
Epidemiological characteristics and laboratory diagnosis of fungal keratitis. A three-year study. Indian J Ophthalmol (2003) 1.93
Possible role of Fc receptors on cells infected and transformed by herpesvirus: escape from immune cytolysis. Infect Immun (1978) 1.93
Method for induction of mutations in physically defined regions of the herpes simplex virus genome. J Virol (1981) 1.89
A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol (1994) 1.86
Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease. Dig Liver Dis (2006) 1.84
Inversion events in the HSV-1 genome are directly mediated by the viral DNA replication machinery and lack sequence specificity. Cell (1988) 1.84
Expression of a human cytomegalovirus late gene is posttranscriptionally regulated by a 3'-end-processing event occurring exclusively late after infection. Mol Cell Biol (1986) 1.78
Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants. J Virol (1988) 1.74
Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem (1980) 1.73
Innovative materials processing strategies: a biomimetic approach. Science (1992) 1.72
Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A (1999) 1.68
Regulation of the herpes simplex virus type 1 late (gamma 2) glycoprotein C gene: sequences between base pairs -34 to +29 control transient expression and responsiveness to transactivation by the products of the immediate early (alpha) 4 and 0 genes. Nucleic Acids Res (1987) 1.68
Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A (1993) 1.65
Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem (1999) 1.64
HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther (2005) 1.63
Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B. J Virol (1993) 1.63
Multicenter clinical and analytical evaluation of the AxSYM troponin-I immunoassay to assist in the diagnosis of myocardial infarction. Clin Chem (1999) 1.62
Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites. J Virol (1985) 1.60
A long-term dose-response study of mitomycin in glaucoma filtration surgery. Arch Ophthalmol (1997) 1.58
Plasma delivery of retinoic acid to tissues in the rat. J Biol Chem (1995) 1.57
Physicians' metered dose inhaler technique after a single teaching session. Ann Allergy Asthma Immunol (1996) 1.56
HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. Am J Clin Nutr (1999) 1.54
Identification of mar mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and function in virus penetration. J Virol (1989) 1.52
Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J Virol (1994) 1.51
Induced mutant mice expressing lipoprotein lipase exclusively in muscle have subnormal triglycerides yet reduced high density lipoprotein cholesterol levels in plasma. J Biol Chem (1997) 1.49
Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Virology (1990) 1.49
Utilisation of eye care services in rural south India: the Aravind Comprehensive Eye Survey. Br J Ophthalmol (2004) 1.48
Mutant analysis of herpes simplex virus-induced cell surface antigens: resistance to complement-mediated immune cytolysis. J Virol (1980) 1.48
Nocardia asteroides keratitis in south India. Indian J Med Microbiol (2007) 1.45
Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity. J Virol (1985) 1.45
PCR-based analysis of herpes simplex virus type 1 latency in the rat trigeminal ganglion established with a ribonucleotide reductase-deficient mutant. J Virol (1994) 1.45
An X Window system for statlab results reporting. Proc Annu Symp Comput Appl Med Care (1993) 1.43
Reducing total dietary fat without reducing saturated fatty acids does not significantly lower total plasma cholesterol concentrations in normal males. Am J Clin Nutr (1992) 1.42
Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol (1999) 1.42
HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther (2005) 1.42
Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther (2001) 1.41
Aetiological diagnosis of microbial keratitis in South India - a study of 1618 cases. Indian J Med Microbiol (2007) 1.41
Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south India. Indian J Ophthalmol (2010) 1.40
Some thoughts on the nature of ectopic parathyroid hormones. Am J Med (1971) 1.39
Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production. J Virol (1986) 1.39
Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol (1992) 1.37
Effect of cross-immunization on monotypic antibody responses to herpes simplex virus types 1 and 2. J Immunol (1976) 1.37
Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. J Virol (1995) 1.37
Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest (1993) 1.37
Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther (2007) 1.37
Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther (1998) 1.36
Prevalence of bacterial pathogens causing ocular infections in South India. Indian J Pathol Microbiol (2010) 1.35
Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci (1996) 1.35
Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. J Gen Virol (1994) 1.35
Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol (2011) 1.34
Molecular basis of the glycoprotein C-negative phenotypes of herpes simplex virus type 1 mutants selected with a virus-neutralizing monoclonal antibody. J Virol (1986) 1.33
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther (1996) 1.31
A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J Virol (1992) 1.29
Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol (2001) 1.29
Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol (2000) 1.28
Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol (2001) 1.27
Relationship between expression of herpes simplex virus glycoproteins and susceptibility of target cells to human natural killer activity. J Exp Med (1983) 1.27
In vivo metabolism of complement. I. Metabolism of the third component (C'3) in acquired hemolytic anemia. J Clin Invest (1969) 1.26
Localization on the herpes simplex virus type 1 genome of a region encoding proteins involved in adsorption to the cellular receptor. J Virol (1990) 1.26
Microbiological studies on septicemic bullfrogs (Rana catesbeiana). Am J Vet Res (1974) 1.26
Persistence of herpes simplex virus genes in cells of neuronal origin. J Virol (1980) 1.25